Market Analysis and Insights: Global Cancer Biopharmaceuticals Market
The research report studies the Cancer Biopharmaceuticals market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Cancer Biopharmaceuticals market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Cancer Biopharmaceuticals Scope and Segment
The global Cancer Biopharmaceuticals market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Biopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Biologics
Biosimilars
by Application, this report covers the following segments
Liquid Cancers
Solid Cancers
Global Cancer Biopharmaceuticals market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Cancer Biopharmaceuticals key players in this market include:
Sanofi
Johnson & Johnson
Pfizer
Novartis
Merck
GlaxoSmithKline
Eli Lilly
Agios Pharmaceuticals
Bristol-Myers Squibb
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
The research report studies the Cancer Biopharmaceuticals market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Cancer Biopharmaceuticals market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Cancer Biopharmaceuticals Scope and Segment
The global Cancer Biopharmaceuticals market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Biopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Biologics
Biosimilars
by Application, this report covers the following segments
Liquid Cancers
Solid Cancers
Global Cancer Biopharmaceuticals market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Cancer Biopharmaceuticals key players in this market include:
Sanofi
Johnson & Johnson
Pfizer
Novartis
Merck
GlaxoSmithKline
Eli Lilly
Agios Pharmaceuticals
Bristol-Myers Squibb
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
1 Market Overview of Cancer Biopharmaceuticals
1.1 Cancer Biopharmaceuticals Market Overview
1.1.1 Cancer Biopharmaceuticals Product Scope
1.1.2 Cancer Biopharmaceuticals Market Status and Outlook
1.2 Global Cancer Biopharmaceuticals Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Cancer Biopharmaceuticals Market Size by Region (2016-2027)
1.4 Global Cancer Biopharmaceuticals Historic Market Size by Region (2016-2021)
1.5 Global Cancer Biopharmaceuticals Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.1 North America Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.2 Europe Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.3 Asia-Pacific Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.4 Latin America Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.5 Middle East & Africa Cancer Biopharmaceuticals Market Size (2016-2027)
2 Cancer Biopharmaceuticals Market Overview by Type
2.1 Global Cancer Biopharmaceuticals Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Cancer Biopharmaceuticals Historic Market Size by Type (2016-2021)
2.3 Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2022-2027)
2.4 Biologics
2.5 Biosimilars
3 Cancer Biopharmaceuticals Market Overview by Application
3.1 Global Cancer Biopharmaceuticals Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Cancer Biopharmaceuticals Historic Market Size by Application (2016-2021)
3.3 Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2022-2027)
3.4 Liquid Cancers
3.5 Solid Cancers
4 Cancer Biopharmaceuticals Competition Analysis by Players
4.1 Global Cancer Biopharmaceuticals Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Biopharmaceuticals as of 2020)
4.3 Date of Key Players Enter into Cancer Biopharmaceuticals Market
4.4 Global Top Players Cancer Biopharmaceuticals Headquarters and Area Served
4.5 Key Players Cancer Biopharmaceuticals Product Solution and Service
4.6 Competitive Status
4.6.1 Cancer Biopharmaceuticals Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Sanofi
5.1.1 Sanofi Profile
5.1.2 Sanofi Main Business
5.1.3 Sanofi Cancer Biopharmaceuticals Products, Services and Solutions
5.1.4 Sanofi Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.1.5 Sanofi Recent Developments
5.2 Johnson & Johnson
5.2.1 Johnson & Johnson Profile
5.2.2 Johnson & Johnson Main Business
5.2.3 Johnson & Johnson Cancer Biopharmaceuticals Products, Services and Solutions
5.2.4 Johnson & Johnson Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.2.5 Johnson & Johnson Recent Developments
5.3 Pfizer
5.5.1 Pfizer Profile
5.3.2 Pfizer Main Business
5.3.3 Pfizer Cancer Biopharmaceuticals Products, Services and Solutions
5.3.4 Pfizer Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis Cancer Biopharmaceuticals Products, Services and Solutions
5.4.4 Novartis Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.4.5 Novartis Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Cancer Biopharmaceuticals Products, Services and Solutions
5.5.4 Merck Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.5.5 Merck Recent Developments
5.6 GlaxoSmithKline
5.6.1 GlaxoSmithKline Profile
5.6.2 GlaxoSmithKline Main Business
5.6.3 GlaxoSmithKline Cancer Biopharmaceuticals Products, Services and Solutions
5.6.4 GlaxoSmithKline Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.6.5 GlaxoSmithKline Recent Developments
5.7 Eli Lilly
5.7.1 Eli Lilly Profile
5.7.2 Eli Lilly Main Business
5.7.3 Eli Lilly Cancer Biopharmaceuticals Products, Services and Solutions
5.7.4 Eli Lilly Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.7.5 Eli Lilly Recent Developments
5.8 Agios Pharmaceuticals
5.8.1 Agios Pharmaceuticals Profile
5.8.2 Agios Pharmaceuticals Main Business
5.8.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Products, Services and Solutions
5.8.4 Agios Pharmaceuticals Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.8.5 Agios Pharmaceuticals Recent Developments
5.9 Bristol-Myers Squibb
5.9.1 Bristol-Myers Squibb Profile
5.9.2 Bristol-Myers Squibb Main Business
5.9.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Products, Services and Solutions
5.9.4 Bristol-Myers Squibb Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.9.5 Bristol-Myers Squibb Recent Developments
5.10 AstraZeneca
5.10.1 AstraZeneca Profile
5.10.2 AstraZeneca Main Business
5.10.3 AstraZeneca Cancer Biopharmaceuticals Products, Services and Solutions
5.10.4 AstraZeneca Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.10.5 AstraZeneca Recent Developments
5.11 Mylan
5.11.1 Mylan Profile
5.11.2 Mylan Main Business
5.11.3 Mylan Cancer Biopharmaceuticals Products, Services and Solutions
5.11.4 Mylan Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.11.5 Mylan Recent Developments
5.12 LEO Pharma
5.12.1 LEO Pharma Profile
5.12.2 LEO Pharma Main Business
5.12.3 LEO Pharma Cancer Biopharmaceuticals Products, Services and Solutions
5.12.4 LEO Pharma Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.12.5 LEO Pharma Recent Developments
5.13 Boehringer Ingelheim
5.13.1 Boehringer Ingelheim Profile
5.13.2 Boehringer Ingelheim Main Business
5.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Products, Services and Solutions
5.13.4 Boehringer Ingelheim Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.13.5 Boehringer Ingelheim Recent Developments
5.14 Alexion Pharmaceuticals
5.14.1 Alexion Pharmaceuticals Profile
5.14.2 Alexion Pharmaceuticals Main Business
5.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Products, Services and Solutions
5.14.4 Alexion Pharmaceuticals Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.14.5 Alexion Pharmaceuticals Recent Developments
5.15 Elusys Therapeutics
5.15.1 Elusys Therapeutics Profile
5.15.2 Elusys Therapeutics Main Business
5.15.3 Elusys Therapeutics Cancer Biopharmaceuticals Products, Services and Solutions
5.15.4 Elusys Therapeutics Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.15.5 Elusys Therapeutics Recent Developments
6 North America
6.1 North America Cancer Biopharmaceuticals Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Cancer Biopharmaceuticals Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cancer Biopharmaceuticals Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cancer Biopharmaceuticals Market Dynamics
11.1 Cancer Biopharmaceuticals Industry Trends
11.2 Cancer Biopharmaceuticals Market Drivers
11.3 Cancer Biopharmaceuticals Market Challenges
11.4 Cancer Biopharmaceuticals Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Cancer Biopharmaceuticals Market Overview
1.1.1 Cancer Biopharmaceuticals Product Scope
1.1.2 Cancer Biopharmaceuticals Market Status and Outlook
1.2 Global Cancer Biopharmaceuticals Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Cancer Biopharmaceuticals Market Size by Region (2016-2027)
1.4 Global Cancer Biopharmaceuticals Historic Market Size by Region (2016-2021)
1.5 Global Cancer Biopharmaceuticals Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.1 North America Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.2 Europe Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.3 Asia-Pacific Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.4 Latin America Cancer Biopharmaceuticals Market Size (2016-2027)
1.6.5 Middle East & Africa Cancer Biopharmaceuticals Market Size (2016-2027)
2 Cancer Biopharmaceuticals Market Overview by Type
2.1 Global Cancer Biopharmaceuticals Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Cancer Biopharmaceuticals Historic Market Size by Type (2016-2021)
2.3 Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2022-2027)
2.4 Biologics
2.5 Biosimilars
3 Cancer Biopharmaceuticals Market Overview by Application
3.1 Global Cancer Biopharmaceuticals Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Cancer Biopharmaceuticals Historic Market Size by Application (2016-2021)
3.3 Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2022-2027)
3.4 Liquid Cancers
3.5 Solid Cancers
4 Cancer Biopharmaceuticals Competition Analysis by Players
4.1 Global Cancer Biopharmaceuticals Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Biopharmaceuticals as of 2020)
4.3 Date of Key Players Enter into Cancer Biopharmaceuticals Market
4.4 Global Top Players Cancer Biopharmaceuticals Headquarters and Area Served
4.5 Key Players Cancer Biopharmaceuticals Product Solution and Service
4.6 Competitive Status
4.6.1 Cancer Biopharmaceuticals Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Sanofi
5.1.1 Sanofi Profile
5.1.2 Sanofi Main Business
5.1.3 Sanofi Cancer Biopharmaceuticals Products, Services and Solutions
5.1.4 Sanofi Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.1.5 Sanofi Recent Developments
5.2 Johnson & Johnson
5.2.1 Johnson & Johnson Profile
5.2.2 Johnson & Johnson Main Business
5.2.3 Johnson & Johnson Cancer Biopharmaceuticals Products, Services and Solutions
5.2.4 Johnson & Johnson Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.2.5 Johnson & Johnson Recent Developments
5.3 Pfizer
5.5.1 Pfizer Profile
5.3.2 Pfizer Main Business
5.3.3 Pfizer Cancer Biopharmaceuticals Products, Services and Solutions
5.3.4 Pfizer Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis Cancer Biopharmaceuticals Products, Services and Solutions
5.4.4 Novartis Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.4.5 Novartis Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Cancer Biopharmaceuticals Products, Services and Solutions
5.5.4 Merck Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.5.5 Merck Recent Developments
5.6 GlaxoSmithKline
5.6.1 GlaxoSmithKline Profile
5.6.2 GlaxoSmithKline Main Business
5.6.3 GlaxoSmithKline Cancer Biopharmaceuticals Products, Services and Solutions
5.6.4 GlaxoSmithKline Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.6.5 GlaxoSmithKline Recent Developments
5.7 Eli Lilly
5.7.1 Eli Lilly Profile
5.7.2 Eli Lilly Main Business
5.7.3 Eli Lilly Cancer Biopharmaceuticals Products, Services and Solutions
5.7.4 Eli Lilly Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.7.5 Eli Lilly Recent Developments
5.8 Agios Pharmaceuticals
5.8.1 Agios Pharmaceuticals Profile
5.8.2 Agios Pharmaceuticals Main Business
5.8.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Products, Services and Solutions
5.8.4 Agios Pharmaceuticals Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.8.5 Agios Pharmaceuticals Recent Developments
5.9 Bristol-Myers Squibb
5.9.1 Bristol-Myers Squibb Profile
5.9.2 Bristol-Myers Squibb Main Business
5.9.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Products, Services and Solutions
5.9.4 Bristol-Myers Squibb Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.9.5 Bristol-Myers Squibb Recent Developments
5.10 AstraZeneca
5.10.1 AstraZeneca Profile
5.10.2 AstraZeneca Main Business
5.10.3 AstraZeneca Cancer Biopharmaceuticals Products, Services and Solutions
5.10.4 AstraZeneca Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.10.5 AstraZeneca Recent Developments
5.11 Mylan
5.11.1 Mylan Profile
5.11.2 Mylan Main Business
5.11.3 Mylan Cancer Biopharmaceuticals Products, Services and Solutions
5.11.4 Mylan Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.11.5 Mylan Recent Developments
5.12 LEO Pharma
5.12.1 LEO Pharma Profile
5.12.2 LEO Pharma Main Business
5.12.3 LEO Pharma Cancer Biopharmaceuticals Products, Services and Solutions
5.12.4 LEO Pharma Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.12.5 LEO Pharma Recent Developments
5.13 Boehringer Ingelheim
5.13.1 Boehringer Ingelheim Profile
5.13.2 Boehringer Ingelheim Main Business
5.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Products, Services and Solutions
5.13.4 Boehringer Ingelheim Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.13.5 Boehringer Ingelheim Recent Developments
5.14 Alexion Pharmaceuticals
5.14.1 Alexion Pharmaceuticals Profile
5.14.2 Alexion Pharmaceuticals Main Business
5.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Products, Services and Solutions
5.14.4 Alexion Pharmaceuticals Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.14.5 Alexion Pharmaceuticals Recent Developments
5.15 Elusys Therapeutics
5.15.1 Elusys Therapeutics Profile
5.15.2 Elusys Therapeutics Main Business
5.15.3 Elusys Therapeutics Cancer Biopharmaceuticals Products, Services and Solutions
5.15.4 Elusys Therapeutics Cancer Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.15.5 Elusys Therapeutics Recent Developments
6 North America
6.1 North America Cancer Biopharmaceuticals Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Cancer Biopharmaceuticals Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cancer Biopharmaceuticals Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cancer Biopharmaceuticals Market Dynamics
11.1 Cancer Biopharmaceuticals Industry Trends
11.2 Cancer Biopharmaceuticals Market Drivers
11.3 Cancer Biopharmaceuticals Market Challenges
11.4 Cancer Biopharmaceuticals Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
